The researchers discovered a mechanism by which a gene, called TNK1, becomes an oncogenic driver in cancer. TNK1 is present in all cells, but when mutated, it becomes dangerous and able to convert normal cells into cancer cells. This puts TNK1 in a select category of cancer driver genes.
"You can think of cancer drivers as the engine that makes cancer grow and progress," said the senior author. The researchers also figured out how mutations in the TNK1 gene cause cancer. It's a significant discovery considering only a handful of other drivers like TNK1 are known to scientists.
"One of the greatest modern challenges of cancer research is identifying new cancer drivers because each one holds the key to a potentially much more effective cancer treatment," said the author.
For years, the senior author has studied a cancer-promoting protein called 14-3-3 that exists at unusually high levels within cancer cells. Six years ago, the author identified TNK1 as an interacting partner of 14-3-3. The research has led to a greater understanding of TNK1 and how it acts as a cancer driver.
After identifying TNK1 six years ago, the researchers began working to understand its properties with the goal of designing and developing a new drug to treat tumors caused by TNK1.
The authors discovered a MARK-mediated phosphorylation on TNK1 at S502 that promotes an interaction between TNK1 and 14-3-3, which sequesters TNK1 and inhibits its kinase activity. Conversely, the release of TNK1 from 14-3-3 allows TNK1 to cluster in ubiquitin-rich puncta and become active. Active TNK1 induces growth factor-independent proliferation of lymphoid cells in cell culture and mouse models.
One unusual feature of TNK1 is a ubiquitin-association domain (UBA) on its C-terminus. The researchers characterize the TNK1 UBA, which has high affinity for poly-ubiquitin. Point mutations that disrupt ubiquitin binding inhibit TNK1 activity. These data suggest a mechanism in which TNK1 toggles between 14-3-3-bound (inactive) and ubiquitin-bound (active) states.
The scientists started designing compounds that would target TNK1 in cancer cells. Through computer modeling and structure-based rational design, they continued to test and then optimize how this compound would react.
The pre-clinical results for the drug, called TP-5801, are extremely promising. TNK1 inhibitor, TP-5801 shows nanomolar potency against TNK1-transformed cells and suppresses tumor growth. The compound has passed FDA-required steps and is now ready for what's called a first-in-human study or phase 1 clinical trial.
https://www.nature.com/articles/s41467-021-25622-3
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Ftnk1-is-a-ubiquitin&filter=22
A new cancer-driving mechanism identified!
- 1,508 views
- Added
Edited
Latest News
Protein that helps COVID-19…
By newseditor
Posted 26 Jul
Spinal Muscular Atrophy (SM…
By newseditor
Posted 26 Jul
Link between bowel movement…
By newseditor
Posted 26 Jul
Inhibition of IL-11 signall…
By newseditor
Posted 25 Jul
Brain changes linked to obe…
By newseditor
Posted 25 Jul
Other Top Stories
Intestinal wound healing in Crohn's disease is compromised by foodb…
Read more
Modeling viral infections using patient-specific "digital twins"
Read more
How SARS-CoV-2 variants escape neutralization?
Read more
Robust intracellular virulence networks detected!
Read more
SARS-CoV-2 within-host diversity and transmission
Read more
Protocols
A systems biology approach…
By newseditor
Posted 24 Jul
quantms: a cloud-based pipe…
By newseditor
Posted 22 Jul
Emerging tools and best pra…
By newseditor
Posted 19 Jul
Directly selecting cell-typ…
By newseditor
Posted 17 Jul
PUFFFIN: an ultra-bright, c…
By newseditor
Posted 16 Jul
Publications
Hepatocyte-intrinsic SMN de…
By newseditor
Posted 26 Jul
Aberrant bowel movement fre…
By newseditor
Posted 26 Jul
A pseudoautosomal glycosyla…
By newseditor
Posted 26 Jul
Microglia protect against a…
By newseditor
Posted 26 Jul
Rigor and reproducibility i…
By newseditor
Posted 26 Jul
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar